[PDF] Top 20 Gestión de residuos de construcción y demolición (RCD) en Bogotá: perspectivas y limitantes
Has 10000 "Gestión de residuos de construcción y demolición (RCD) en Bogotá: perspectivas y limitantes" found on our website. Below are the top 20 most common "Gestión de residuos de construcción y demolición (RCD) en Bogotá: perspectivas y limitantes".
Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
... denilekin diftitox in combination therapy. A combination trial of denileukin diftitox with bexarotene has shown increased activity over ...profiles, denileukin diftitox has also been ... See full document
79
Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat
... dose modifications were allowed: 300 mg daily or 300 mg daily for 5 days per week. Safety assessments were performed with the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. ... See full document
34
Novel therapeutic agents for cutaneous T-Cell lymphoma
... photopheresis, denileukin diftitox, vorinostat, alemtuzumab, cytotoxic chemotherapy, or combination ...no treatment for which improved survival has been demonstrated ...stem cell transplant is ... See full document
6
STAT5 induces miR-21 expression in cutaneous T cell lymphoma
... important role in the pathogenesis and disease progression of CTCL ...by denileukin diftitox, an engineered combination of IL-2 and Diphtheria toxin (Ontac) ...malignant cell proliferation and ... See full document
121
Role of everolimus in the treatment of renal cell carcinoma
... clear cell histology, measurable disease, adequate organ function, absence of central nervous system metastasis, Zubrod performance status (ZPS) of 2 or better and no more than 1 prior ... See full document
94
<p>Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma</p>
... Abstract: Cutaneous T-cell lymphoma (CTCL) poses unique treatment challenges, given its range of presentations and numerous systemic therapy ...of treatment options for advanced ... See full document
14
<p>Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel</p>
... As a first step, patients have to be investigated with a clinical and histological confrontation. Blood and sometimes blood- marrow investigations, as well as radiological tests, are to be staged following EORTC ... See full document
29
No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T cell neoplasms
... lates. A common feature of the Deltaretrovirus genus is the use of proline tRNA as a primer for the complemen- tary minus-strand DNA synthesis. tRNA genes are highly conserved between different species [15]. Alignment of ... See full document
11
Mechanisms of lymphocytotoxicity induced by extracorporeal photochemotherapy for cutaneous T cell lymphoma
... photochemotherapy for cutaneous T cell lymphoma is apparently mediated by DNA damage, subsequent poly (ADP-ribosyl)ation and adenine nucleotide depletion. It is not known how the DNA damage ... See full document
8
Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma
... benign T cells clarifies how it can treat both cutaneous lym- phoma and inflammatory disorders such as ...benign T cell ...benign T cells; treatment of patients with antibiotics ... See full document
16
Atypical Cutaneous Lymphoproliferative Disorder: A Fatal Mimic of Cutaneous T Cell Lymphoma in a Patient with HIV Infection
... alternative cutaneous T-cell lymphoma (CTCL), including Sézary’s syndrome and adult T-cell leukemia/lymphoma ...atypical T-cells in peripheral blood and hepatosple- ... See full document
69
Detection of Chlamydophila pneumoniae and human herpesvirus 8 in primary cutaneous anaplastic large-cell lymphoma: a case report
... a role in oncogenesis for their tendency to cause persistent infections and chronic antigenic ...-specific T cells throughout the release of Sézary T cell-activating factor (SAF), thus ... See full document
15
<p>Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy</p>
... Acalabrutinib was fi rst studied in R/R MCL in a Phase 2, multicenter international open-label study (ACE-LY-004). The study took place from March 2015 until January 2016 at 40 sites across 10 countries with enrollment of ... See full document
7
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
... Although most of the diarrheal events in the combination group were grade 1 or 2, 12% were grade 3 and 1% were grade 4. Rates of treatment discontinuation because of AEs were similar between the two arms (13% in ... See full document
24
The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder
... chotic, which received regulatory approval in August 2009 by the US Food and Drug Administration (FDA) for the acute treatment of schizophrenia and for the acute treatment of manic or mixed episodes ... See full document
6
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
... was performed on one of these patients and showed acute necrotizing pancreatitis with no evidence of cholelithiasis. The remaining cases were grade 3 or 4 in severity. In seven cases, the dosing of BV was 1.8 mg/kg every ... See full document
11
Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
... daily oral dose of vorinostat until disease progression or unac- ceptable toxicity. Two patients survived progression-free for over 6 months and one partial response was observed. The grade 4 toxicities were leucopenia ... See full document
28
The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer
... The OS outcomes of these trials have been criticized since only a minority of patients in the placebo arms went on to receive the trial agent on progression. This raises the question of whether the observed effect simply ... See full document
10
Adult t cell leukemia/ lymphoma: from epidemiology to treatment
... peripheral T lymphomas: a few months in the acute form, 1 to 5 years in the chronic form, 1 to 2 years in the lymphomatous form and up to 10 years in the form of slow ... See full document
6
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
... kill T cell lymphoma cells that express the IL-2 ...that denileukin diftitox also can kill normal T cells that express ...of denileukin diftitox may be on depleting ... See full document
23
Related subjects